The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease

Published:2016-05-12 Issue:10 Volume:36 Page:1549-1557
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Kazankov Konstantin¹,Barrera Francisco²³,Møller Holger Jon⁴,Rosso Chiara⁵,Bugianesi Elisabetta⁵,David Ezio⁶,Ibrahim Kamal Jouness Ramy⁵,Esmaili Saeed²,Eslam Mohammed²,McLeod Duncan⁷,Bibby Bo Martin⁸,Vilstrup Hendrik¹,George Jacob²,Grønbaek Henning¹

Affiliation:

1. Department of Hepatology and Gastroenterology; Aarhus University Hospital; Aarhus Denmark

2. The Storr Liver Centre; Westmead Institute for Medical Research; University of Sydney and Westmead Hospital; Westmead NSW Australia

3. Department of Gastroenterology; Pontificia Universidad Católica; Santiago Chile

4. Department of Clinical Biochemistry; Aarhus University Hospital; Aarhus Denmark

5. Division of Gastroenterology and Hepatology; Department of Medical Sciences; University of Torino; Torino Italy

6. Division of Pathology; Department of Medical Sciences; University of Torino; Torino Italy

7. Department of Anatomical Pathology; Institute of Clinical Pathology and Medical Research (ICPMR); Westmead Hospital; Westmead NSW Australia

8. Department of Biostatistics; Aarhus University; Aarhus Denmark

Funder

NOVO Nordisk Foundation

The Danish Strategic Research Council

Savvaerksejer Jeppe Juhl og hustru Ovita Juhls mindelegat

National Health and Medical Research Council

Sydney Medical Foundation, University of Sydney

Seventh Framework Programme

project FLIP

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13150/fullpdf

Reference41 articles.

1. Macrophage heterogeneity in liver injury and fibrosis;Tacke;J Hepatol,2014

2. Kupffer cells in non-alcoholic fatty liver disease: the emerging view;Baffy;J Hepatol,2009

3. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice;Tomita;Gut,2006

4. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production;Tosello-Trampont;J Biol Chem,2012

5. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease;Moller;Eur J Haematol,2004

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A potential novel stratification model to predict cardiovascular disease in patients with metabolic dysfunction-associated steatotic liver disease;European Journal of Internal Medicine;2024-09

2. Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis;Metabolism and Target Organ Damage;2024-08-22

3. Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy;Biomolecules;2024-06-14

4. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD;Current Obesity Reports;2024-05-29

5. Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease;Frontiers in Immunology;2024-05-15